Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Stock markets recover opening losses
Fri, 25 Nov 11:30 am

Indian stock market indices have recovered some of their opening losses and are now trading marginally weak. Among sectoral indices, capital goods and realty stocks are leading the gains while stocks from the IT and Oil and gas sectors are at the receiving end.

The BSE-Sensex is trading down by 22 points and NSE-Nifty is trading weak by 7 points. However, BSE Mid Cap and BSE Small Cap indices are trading up by 1.1% and 1.2% respectively. The rupee is trading at 52.21 to the US dollar.

Finance stocks are trading strong today. The gains are led by Power Finance Corporation (PFC) and Crisil. As per a leading financial daily, Infrastructure Development Finance Company (IDFC) is likely to increase its loan exposure to the transportation sector, diverting it from the troubled power sector. As per the management, the road sector is picking up well and is expected to offer better opportunities for the company. The company expects more than Rs 150 bn to Rs 200 bn worth of road projects to be bid out in the future. IDFC lends only to private players and will now be extra cautious in lending to this sector on account of the issues that will take time to resolve. The company presently is raising funds through retail long term infrastructure bonds and also aims to tap offshore market to get access to cheap funds in the wake of rising domestic interest rates. The company has a target to achieve 15% year on year credit growth. The stock was trading in the green.

Pharma stocks are trading firm. Ranbaxy and Orchid Chemicals are the top gainers. As per a leading financial daily, Ranbaxy Laboratories and the American authorities are close to a settlement regarding Ranbaxy's regulatory troubles in the US. The settlement is expected to be favourable for the company's launch of the low cost version of Lipitor (cholesterol lowering drug) scheduled next week. Back in 2008, an agreement between Ranbaxy and Pfizer allowed the former to launch the drug on November 30, 2011. However, in the same year, the US Food and Drug Administration (USFDA) had banned the company from selling 30 drugs and fresh products (from its two Indian plants) in the US since the company was found guilty of violating US manufacturing practices. Ranbaxy is expected to pay US$ 350 - 400 m as penalty to settle the issues with the regulator and also get approval to sell the generic version of Lipitor in the US market. The stock was trading in the green.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Stock markets recover opening losses". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.